Xanodyne Pharmaceuticals, Inc., founded in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. We market a portfolio of revenue generating products consisting of prescription pharmaceuticals and a line of prenatal vitamins, and we are advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.

We are developing: Zipsor™ for the treatment of mild to moderate acute pain for which we have received an Approvable Letter from the U.S. Food & Drug Administration (FDA); XP12B for the treatment of menorrhagia (heavy menstrual bleeding) has recently received top line Phase 3 clinical data and NDA filing is being completed; and XP20B for the treatment of mild to moderate pain for which a Phase 3 trial has been completed in the U.S.